Abstract
REDUX: A Multicenter, Open-Label Study of DM199 (Recombinant Human Tissue Kallikrein-1) in Patients with Stage 2 or 3 CKD
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
